Contineum Therapeutics (CTNM) Net Equity Issued and Repurchased (2024 - 2025)
Contineum Therapeutics (CTNM) posted quarterly Net Equity Issued and Repurchased of $99.2 million for Q4 2025, up 422.11% quarter-over-quarter from $19.0 million in Q3 2025.
Powered by 
Analysis
Contineum Therapeutics (CTNM) Net Equity Issued and Repurchased (2024 - 2025) Analysis & Trends
Contineum Therapeutics' Net Equity Issued and Repurchased history runs 2 years deep, the most recent figure standing at $99.2 million for Q4 2025.
- In Q4 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $99.2 million; the TTM figure through Dec 2025 stood at $118.2 million (up 37906.43% YoY), while the FY2025 annual figure was $93.2 million, down 13.83% from the prior year.
- Net Equity Issued and Repurchased for Q4 2025 stood at $99.2 million, up from $19.0 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $99.2 million in Q4 2025, with the low at $311000.0 in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Contineum Therapeutics | 628.34 Mn | 628.34 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 99.20 Mn |
| Sep 30, 2025 | 19.00 Mn |
| Jun 30, 2024 | 311,000.00 |